Key result
A post hoc analysis evaluated switching from rivaroxaban and aspirin to aspirin alone over a median follow-up of 1.02 years, but efficacy results were not reported in the truncated abstract.
Why the study?
Does switching from rivaroxaban and aspirin to aspirin alone after early trial termination affect cardiovascular outcomes in high-risk patients with chronic coronary syndromes or PAD?
RCT
Open-label
null
Yes
Does switching from rivaroxaban and aspirin to aspirin alone after early trial termination affect cardiovascular outcomes in high-risk patients with chronic coronary syndromes or PAD?
No takes yet. Share an insight, caveat, or question.
This editorial highlights the medical, ethical, and regulatory challenges of stopping a trial early for efficacy, using the COMPASS trial post-hoc analysis as a case study.
Darmon et al. (2021) conducted an RCT in Chronic coronary syndromes and/or peripheral arterial disease. Switching to non-study aspirin vs. Combination of low-dose rivaroxaban and aspirin was evaluated on Composite of cardiovascular (CV) death, myocardial infarction (MI), stroke, its individual components and limb events. A post hoc analysis evaluated switching from rivaroxaban and aspirin to aspirin alone over a median follow-up of 1.02 years, but efficacy results were not reported in the truncated abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: